Screener
Gilead Sciences GILD Proceeds from debt financing, net of issuance costs
Proceeds from debt financing, net of issuance costs at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromDebtNetOfIssuanceCosts.
The source filing: Gilead Sciences’s 10-K, filed February 24, 2026.
- Filed
- Feb 24, 2026, 4:18 PM EST
- Fiscal year
- FY2025
- Accession
- 0000882095-26-000006
| (in millions) | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Other investing activities, net | 2 | 58 | (1) |
| Net cash used in investing activities | (4,793) | (3,449) | (2,265) |
| Financing Activities: | |||
| Proceeds from debt financing, net of issuance costs | — | 3,464 | 1,980 |
| Proceeds from issuances of common stock | 408 | 422 | 232 |
| Repurchases of common stock under repurchase programs | (1,922) | (1,150) | (1,000) |
| Repayments of debt and other obligations | (1,788) | (1,970) | (2,250) |
| Payments of dividends | (4,003) | (3,918) | (3,809) |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Gilead Sciences's proceeds from debt financing, net of issuance costs?
- Gilead Sciences (GILD) reported proceeds from debt financing, net of issuance costs of $0 in Q4 2025.
- How has Gilead Sciences's proceeds from debt financing, net of issuance costs changed year-over-year?
- Gilead Sciences's proceeds from debt financing, net of issuance costs decreased by 100.0% year-over-year, from $3.46B to $0.
- What does proceeds from debt financing, net of issuance costs mean?
- Proceeds from debt financing, net of issuance costs
Ask your AI about Gilead Sciences's proceeds from debt financing, net of issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude